Regeneron’s myasthenia gravis therapy is under US and EU review
Regeneron’s experimental therapy, cemdisiran, is being reviewed by US and European regulators.
The therapy, developed with Alnylam Pharmaceuticals, is for the rare autoimmune condition myasthenia gravis.
The US FDA has issued priority review after considering a priority review voucher.